Shanghai Pharmaceutical cooperates with Sichuan University in the research and development of new anti pulmonary fibrosis drugs

On July 19, Shanghai Pharmaceutical (02607) launched a cooperation project with Sichuan University to develop a new class 1 anti pulmonary fibrosis drug The cooperation will be carried out between the Academy of Chinese medicine and the State Key Laboratory of biotherapy of Sichuan University It is reported that the State Key Laboratory of biotherapy of Sichuan University is the only State Key Laboratory of biotherapy in China Academician Wei Yuquan is currently vice president of Sichuan University He was elected academician of Chinese Academy of Sciences in 2003 for his contribution in the field of tumor biotherapy He has been committed to the research of cellular immunotherapy and precision medicine earlier in China, and his research team now has more than 1000 R & D personnel It is understood that pulmonary fibrosis is caused by the self repair of human body when fibrocytes are injured When pulmonary fibrosis progresses, it will cause progressive dyspnea in fibrotic patients Due to the worsening air environment and the increase of PM2.5 in city, the incidence rate of pulmonary fibrosis is increasing in major cities of China Academician Wei Yuquan expressed the hope that the anti fibrosis drug research and development project with Shanghai Pharmaceutical will be successful and listed as soon as possible It is worth mentioning that SHP is committed to R & D and innovation In the first half of this year, one class 1 new drug has been applied for clinical application and two class 1 new drugs have been approved for clinical application In recent years, Shanghai Pharmaceutical has established strategic partnership with Shenyang Pharmaceutical University and the Second Military Medical University in order to enhance the technological advantages of products and research product chain In terms of performance, the company's operating revenue has exceeded 100 billion yuan last year, and the company has invested a lot in drug research and development By the end of December 2015, SHP's annual revenue was 105.517 billion yuan (RMB, the same below), an increase of 14.20% year on year, and its net profit was 2.877 billion yuan, an increase of 11.03% year on year In addition, in 2015, SHP invested a total of 617.6908 million yuan in R & D, accounting for 5.22% of the company's industrial sales revenue, of which 26.98% went to innovative drug R & D.